Drug Search Results
More Filters [+]

CP-868,596

Alternative Names: cp-868,596, cp868,596, cp 868,596
Latest Update: 2024-04-05
Latest Update Note: PubMed Publication

Product Description

crenolanib besylate in newly diagnosed diffuse intrinsic pontine glioma (DIPG) and recurrent high-grade glioma (HGG). (Sourced from: https://meetinglibrary.asco.org/record/91991/abstract)

Mechanisms of Action: FLT3 Inhibitor,PGFR Inhibitor

Novel Mechanism: No

Modality: Small Molecule

Route of Administration: Oral

FDA Designation: None *

Approval Status: Not Approved

Approved Countries: None

Approved Indications: None

Known Adverse Events: None

Company: Arog
Company Location:
Company CEO:
Additonal Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for CP-868,596

Countries in Clinic: United States

Active Clinical Trial Count: 1

Highest Development Phases

Phase 2: Acute Myeloid Leukemia

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success

ARO-009

P2

Completed

Acute Myeloid Leukemia

2022-05-01

Recent News Events